Sanofi has announced that it will lower the list price of its insulin drug, Lantus, by 78 percent and will set a $35 cap on out-of-pocket costs for all patients.
The price change and cap will go into effect starting January 1, 2024. They follow a series of moves made last year to lower the price of diabetes medicine, including the launch of an unbranded version of Lantus and a $35 cap for uninsured patients.
Yet, Olivier Bogillot, head of U.S. general medicines at Sanofi, said "the health system was unable to take advantage of it due to its inherent structural challenges."
“Sanofi believes that no one should struggle to pay for their insulin and we are proud of our continued actions to improve access and affordability for millions of patients for many years," he said. "Our decision to cut the list price of our lead insulin needs to be coupled with broader change to the overall system to actually drive savings for patients at the pharmacy counter.”
Sanofi will also cut the price of short-acting Apidra by 70 percent.
Ford Motor Co. is resuming construction on a Michigan electric vehicle battery plant that the company postponed two months ago during a strike by the United Auto Workers union.
The marketing slogan for Stanley Tumbler flask products is built for life and it looks like one video proves that to be true after a woman showed her burned-out car on TikTok along with her Tumbler cup, which was left undamaged.
Nvidia's stock closed at an all-time high Monday at above $504 a share, ahead of the company's latest quarterly earnings report which is due out later Tuesday.
The CEOs of three popular tech companies have been subpoenaed by the Senate Judiciary Committee, which ordered the heads of Discord, Snap and X to testify at a hearing on protecting children online.
'X' owner Elon Musk says he is suing watchdog group Media Matters after the group published an analysis writing that the social media company was placing advertisements from several brands next to anti-Semitic content.
